| PRISM Stock Indexes | Current Value | % Change (Daily) | % Change (Inception) | Most Active | Top % Gainers | Top % Losers |
|---|---|---|---|---|---|---|
| Cannabis | $70.50 | -6.5% | -29.5% | TLRY 25,764 | TCNNF 1.297% | CRON -13.687% |
| EV | $70.60 | -6% | -29.4% | GOEV 12,174 | SPAQ 5.556% | WKHS -24.161% |
| Gene Therapy | $63.70 | -2.5% | -36.3% | BLUE 7,817 | ATRA 29.201% | FIXX -16.667% |
| MedDevices | $191.30 | -3.9% | 91.3% | ATRS 5,230 | SWAV 17.063% | CRMD -57.447% |
| MedDiagnostics | $110.80 | -6.9% | 10.8% | TTOO 10,426 | CSTL 7.584% | QTRX -54.76% |
| Solar | $109.70 | 0.9% | 9.7% | HYSR 7,525 | SUNW 9.609% | SOL -5.394% |
| Uranium | $93.10 | -2.8% | -6.9% | UEC 12,228 | BKUCF 0.489% | DNN -4.839% |
| Vaccines & Cell Therapy | $232.90 | -3.8% | 132.9% | SIGA 16,599 | GMDA 13.364% | NVAX -29.642% |
| Web 3.0 | $58.60 | -4.8% | -41.4% | MARA 18,162 | FTFT 5.464% | PBTS -10.563% |
HONG KONG (Reuters) – Lenovo Group (OTC:LNVGY), the world’s biggest maker of personal computers, reported flat revenue for the April-June quarter when many Chinese cities…
[Read More]
The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.
Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.
Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors
Read more about Soligenix, Inc.
Armed with near-term catalyst, VIRI is poised for next growth stage
Development-stage biotechnology company Virios Therapeutics (NASDAQ:”VIRI”) is working to advance a new therapeutic approach, one that is focused on addressing a potential root cause of Fibromyalgia (FM), a catalyst the company believes is related to activation of previously dormant herpes virus infection. VIRI is anticipating top line results this September from its ongoing FM Phase 2b trial, featuring its lead combination antiviral development candidate, oral IMC-1. An earlier FM Phase 2a study demonstrated IMC-1’s effectiveness and tolerability better than placebo, which could serve as a distinguishing differentiating feature of IMC-1 versus other approved FM treatments.
FM is a medical condition experienced by approximately 2% of the population and is characterized by severe, widespread pain and fatigue, as well as symptoms pertaining to impaired mental health, such as anxiety and depression. Unfortunately, many patients suffering from FM are dissatisfied with available FM treatments. This dissatisfaction relates to both the limited FDA approved treatment options, all of which are focused solely on symptom management, and the burdensome side-effects often resulting in discontinuation of these approved therapies.
We sat down with Virios CEO Greg Duncan to find out more about the company’s research programs, target diseases and upcoming milestones.
Gold futures are setting up for a possible inverse head and shoulders – we are approaching the neckline here. If we break it, a move into the high 1,800’s is likely. Very interesting inflection point – given the backdrop of fed moves and inflation expectations, etc.
